BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enflonsia (Clesrovimab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Enflonsia (Clesrovimab)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07824167-11243@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Enflonsia (Clesrovimab): Phase 4 readout est. (NCT07824167)
DESCRIPTION:Enflonsia (Clesrovimab)\, phase 4.\nStudy: The EMBRACE Study: E
 nflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation\nEst
 imated primary completion: March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/clesrovimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07824167
URL:https://assetmemo.bio/drug/clesrovimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
